Trial · NCT04590586
Results by group505
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 505
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29 | Lanadelumab + Standard of Care | 10.0 | 95% Confidence Interval 5.00 to NA | days | |
| Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29 | Lanadelumab Placebo Control | 15.5 | 95% Confidence Interval 8.00 to NA | days | |
| Apremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29 | Apremilast + Standard of Care | 14.0 | 95% Confidence Interval 11.00 to 15.00 | days | |
| Apremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29 | Apremilast Placebo Control | 14.0 | 95% Confidence Interval 11.00 to 15.00 | days | |
| Zilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29 | Zilucoplan + Standard of Care | 14.0 | 95% Confidence Interval 11.00 to 22.0 | days | |
| Zilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29 | Zilucoplan Placebo Control | 15.0 | 95% Confidence Interval 11.00 to 22.00 | days | |
| Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29 | Lanadelumab + Standard of Care | 52.0 | 95% Confidence Interval 31.31 to 72.20 | percentage of participants | |
| Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29 | Lanadelumab Placebo Control | 56.7 | 95% Confidence Interval 37.43 to 74.54 | percentage of participants | |
| Lanadelumab Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29 | Lanadelumab + Standard of Care | 72.0 | 95% Confidence Interval 50.61 to 87.93 | percentage of participants | |
| Lanadelumab Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29 | Lanadelumab Placebo Control | 63.3 | 95% Confidence Interval 43.86 to 80.07 | percentage of participants | |
| Lanadelumab Sub-protocol: Percentage of Participants Who Died Before or on Day 29 | Lanadelumab + Standard of Care | 32.0 | 95% Confidence Interval 14.95 to 53.50 | percentage of participants | |
| Lanadelumab Sub-protocol: Percentage of Participants Who Died Before or on Day 29 | Lanadelumab Placebo Control | 30.0 | 95% Confidence Interval 14.73 to 49.40 | percentage of participants | |
| Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29 | Lanadelumab + Standard of Care | Day 8 / 1 (Death or discharged to hospice care) | 3 | Participants | |
| Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29 | Lanadelumab Placebo Control | Day 8 / 1 (Death or discharged to hospice care) | 3 | Participants | |
| Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29 | Lanadelumab + Standard of Care | Day 8 / 2 (Hospitalized on invasive mechanical ventilation or ECMO) | 4 | Participants | |
| Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29 | Lanadelumab Placebo Control | Day 8 / 2 (Hospitalized on invasive mechanical ventilation or ECMO) | 6 | Participants | |
| Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29 | Lanadelumab + Standard of Care | Day 8 / 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices) | 3 | Participants | |
| Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29 | Lanadelumab Placebo Control | Day 8 / 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices) | 4 | Participants | |
| Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29 | Lanadelumab + Standard of Care | Day 8 / 4 (Hospitalized, requiring supplemental oxygen) | 2 | Participants | |
| Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29 | Lanadelumab Placebo Control | Day 8 / 4 (Hospitalized, requiring supplemental oxygen) | 6 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04590586/results